Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ203 in advanced solid tumors and TNBC
NCT07190469Phase 1Recruiting
- Sponsor
- ProteinQure
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PQ203 in triple-negative breast cancer (TNBC) and solid tumor, sponsored by ProteinQure. Primary endpoints: Treatment-Emergent Adverse Events, Recommended Phase 2 Dose and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
PQ203
03
Conditions
triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT07190469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190469.